Zimbabwe has rejected a substantial American healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years over Washington's request for sensitive data.
This rejection became public after a internal memorandum dated December was disclosed, revealing that President Emmerson Mnangagwa believed the arrangement was "skewed".
An official spokesman has since stated that the US was demanding access to genetic material for research and commercial purposes while was unwilling to share the benefits from future vaccines.
"We are forced to start the difficult and regrettable task of winding down our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had donated more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for further talks to secure a deal agreeable to both sides so the country's critical HIV treatment initiative can continue.
Wider Background
This development follows a comparable situation in Kenya, where a court suspended a related deal with the US following legal challenges were filed about the security of citizens' health data.
Since resuming the presidency recently, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
The agency had overseen assistance for the American government, but Trump argued its spending was "wasteful" and his administration was pursuing direct bilateral agreements to enhance openness and responsibility.
Based on statements, Sixteen African countries have to date signed these new health pacts, constituting over $18.3bn in committed funds.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation could have provided significant advantages for Zimbabwean communities, particularly the 1.2 million men, women and children currently receiving HIV treatment via American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, with no equivalent assurance of benefiting from any medical innovations – like new medicines or tests – that could be developed from that shared data," he stated.
"In essence, our country would supply the raw materials for medical research without any assurance that the end products would be accessible to our population if a new health crisis arise."
Sovereignty and Global Health
Mangwana further said that the American exit from the global health body and its pursuit of bilateral deals were disrupting frameworks previously set up via the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework created to manage potential pandemics.
"This framework is designed to guarantee that when a country contributes its information, the benefits – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the resources to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We welcome ongoing discussions with our US partners on how subsequent co-operation could be designed in a manner that honours the sovereignty and dignity of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the official position, but recommended that talks should continue given that a large portion of the country's HIV programmes depended on foreign aid.
"Where specific concerns exist, such as those relating to information security or implementation frameworks, these can frequently be addressed through detailed discussion and negotiated safeguards," it said.
The situation emphasises the ongoing tensions between receiving vital international aid and safeguarding a country's data in an ever more data-driven world.